Wire · opportunities
Supplement Industry Plants Longtime Use Flag As US Looks At Expanding Peptide Bulk Drugs List
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 20 July 2026 · Fusion42 review
The supplement industry is lobbying to include peptides in the FDA's compounding bulk drug list expansion, seeking to legitimise longtime use of peptide ingredients under a regulatory umbrella currently reserved for pharmaceuticals. The move could reshape how peptide-based supplements are classified and regulated in the US market.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
If you're selling peptide supplements, the industry just opened a door to FDA legitimacy that your competitors don't know about yet. An advisory committee vote on peptide inclusion in the compounding bulk drug list could move your product from 'unregulated supplement' to 'regulated active ingredient'—that's regulatory cover and a moat.
◆ Coverage
1 source · 20 Jul 2026
◆ Related on Wire
◆ Topics